低分子肝素预防深静脉血栓形成的临床效果分析  

Analysis of clinical effect of low molecular weight heparin in preventing deep vein thrombosis

在线阅读下载全文

作  者:刘卫 LIU Wei(Department of Internal Medicine,Yixing Second People's Hospital(Yixing Occupational Disease Prevention Hospital),Yixing 214221,China)

机构地区:[1]宜兴市第二人民医院(宜兴市职业病防治院)内科,214221

出  处:《中国实用医药》2025年第5期27-30,共4页China Practical Medicine

摘  要:目的分析对需要预防深静脉血栓形成患者应用低分子肝素的临床效果。方法60例需要预防深静脉血栓形成患者,采用随机数字表法分为对照组和观察组,各30例。对照组应用常规治疗,观察组在对照组基础上应用低分子肝素进行预防治疗。比较两组深静脉血栓发生率、凝血功能指标、血液流变学指标、不良反应发生率。结果观察组深静脉血栓发生率0低于对照组的13.33%,差异明显(P<0.05)。治疗后,观察组纤维蛋白原(FIB)(2.68±0.21)g/L低于对照组的(3.34±0.20)g/L,活化部分凝血活酶时间(APTT)(35.14±4.50)s、凝血酶原时间(PT)(13.64±1.09)s均长于对照组的(29.23±4.44)、(12.38±1.17)s,差异明显(P<0.05)。治疗后,观察组全血高切粘度(5.83±0.54)mPa·s、全血低切粘度(3.74±0.54)mPa·s、血小板聚集率(57.06±3.12)%均低于对照组的(6.52±0.65)mPa·s、(5.18±0.62)mPa·s、(63.64±3.20)%,差异明显(P<0.05)。两组不良反应发生率比较,无明显差异(P>0.05)。结论对需要预防深静脉血栓形成患者应用低分子肝素,深静脉血栓发生率较低,凝血功能得以改善,同时血液流变学指标水平降低,整体安全性得以保障,不良反应发生率较低,有很高临床应用价值,值得推广应用。Objective To analyze the clinical effect of low molecular weight heparin in preventing deep vein thrombosis.Methods 60 patients needing prevention of deep vein thrombosis were divided into a control group and an observation group according to random numerical table,with 30 cases in each group.The control group was treated with conventional treatment,and the observation group was treated with low molecular weight heparin on the basis of the control group.The incidence of deep vein thrombosis,coagulation function index,hemorheology indicators and incidence of adverse reactions were compared between the two groups.Results The incidence of deep vein thrombosis of 0 in the observation group was lower than 13.33%in the control group,and the difference was significant(P<0.05).After treatment,the observation group had a lower fibrinogen(FIB)of(2.68±0.21)g/L than(3.34±0.20)g/L in the control group;in the observation group,the activated partial thromboplastin time(APTT)was(35.14±4.50)s and the prothrombin time(PT)was(13.64±1.09)s,which were longer than(29.23±4.44)and(12.38±1.17)s in the control group;the differences were significant(P<0.05).After treatment,the whole-blood high-shear viscosity in the observation group was(5.83±0.54)mPa·s,the whole blood low-shear viscosity was(3.74±0.54)mPa·s,and the platelet aggregation rate was(57.06±3.12)%,which were significantly lower than(6.52±0.65)mPa·s,(5.18±0.62)mPa·s,and(63.64±3.20)%in the control group,and the differences were significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The application of low molecular weight heparin in patients who need to prevent deep vein thrombosis results in a lower incidence of deep vein thrombosis,improved coagulation function,lower levels of hemorheological indicators,overall safety,and a lower incidence of adverse reactions.It has high clinical application value and is worthy of promotion and application.

关 键 词:低分子肝素 预防 深静脉血栓形成 凝血功能 不良反应 

分 类 号:R47[医药卫生—护理学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象